LOADING
Comparing JPMorgan Chase (JPM) and Johnson & Johnson (JNJ) across the Financials and Health Care sectors. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JPM | JNJ |
|---|---|---|
| Price | $351.58 | $270.24 |
| Change Today | +0.01% | +1.07% |
| Market Cap | $934.5B | $651.3B |
| P/E Ratio | 15.3 | 31.1 |
| Forward P/E | 15.0 | 22.9 |
| PEG Ratio | 1.75 | 4.68 |
| EPS | $22.96 | $8.70 |
| Revenue Growth (YoY) | 30.4% | 6.6% |
| Profit Margin | 34.9% | 21.5% |
| Return on Equity | 17.8% | 25.7% |
| Dividend Yield | 1.68% | 1.96% |
| Beta | 0.98 | 0.23 |
| 52-Week High | $366.50 | $276.47 |
| 52-Week Low | $276.44 | $170.33 |
| Volume | 8.1M | 6.2M |
JPMorgan Chase is the larger company by market capitalization. JPMorgan Chase trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Johnson & Johnson offers a higher dividend yield for income investors. JPMorgan Chase has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.